A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Eribulin (Primary) ; Gemcitabine; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms EG-PG
- 13 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 13 Oct 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 02 Jun 2017 Primary endpoint has not been met. (Progression free survival) as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology